NCI is developing an open-source application intended to make it easier for patients and physicians to get information on clinical trials supported by the institute.
A group of melanoma experts, joined by three advocacy groups focused on melanoma, has engaged FDA in a public discussion of the challenges of developing new drugs in the refractory setting and the role crossover can play in such trials.
